About Us

How Can My Company Participate?

Useful Links

These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling.

Drug Details

Company Name Business Partner Drug Name Generic Name Unique ID Studied Indications or Disease Phase Approved Drug Label
TAP Pharmaceutical Products Inc. Prevacid Lansoprazole NCT 00220818 GERD
Pediatric acceptability and tolerability
Phase I http://pitap.abbott.com/showpi.asp?PI=prevacid
Clinical Study Summary Study C03-043
A Phase I, Single- and Repeated- Dose, Randomized, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics Pharmacodynamics and Safety of Lansoprazole in Infants with Clinically-Evident Gastroesophageal Reflux Disease.


The content of this web site is supplied for informational purposes only and should not be construed as medical advice. Patients should consult their health care professional for advice on their specific situation.

Nothing in TAP’s posting of information is intended to be viewed as any claim for a particular marketed or unmarketed product. Some clinical studies may include information not contained in the approved package insert. Please refer to the full prescribing information for additional information.

TAP Pharmaceutical Products Inc. (“TAP”) will use reasonable efforts to include accurate and up-to-date information consistent with TAP policies and procedures, on the ClinicalStudyResults.org web site. However because the status of studies often changes, TAP makes no warranties or representations of any kind as to the current status or completeness of the information contained therein.

Persons accessing and using information posted by TAP on the ClinicalStudyResults.org web site do so at their own risk. TAP hereby disclaims all warranties, express or implied, including warranties of merchantability of fitness for a particular purpose. TAP shall not be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use or inability to use information posted by TAP on the ClinicalStudyResults.org web site, or any errors or omission in the content thereof.

To view this study on clinicaltrials.gov: http://www.clinicaltrials.gov/ct/show/NCT00220818

For FDA Safety Alerts and Recalls refer to the following link: www.fda.gov/MEDWATCH/safety.htm

Springer M, Atkinson S, North J, Raanan M.
Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year.
Pediatr Drugs. 2008 Apr;10(4):255-263.
PubMed Number:18590344

Zhang W, Kukulka M, Witt G, Sutkowski-Markmann D, North J, Atkinson S.
Age-dependent pharmacokinetics of lansoprazole in neonates and infants.
Pediatr Drugs. 2008 Apr;10(4):265-274.
PubMed Number:18590345
Company Study
Study Synopsis C03-043
Back to Search Results

 

 

© 2010 ClinicalStudyResults.org   |  Privacy Policy  |  Contact Us